TheraRadar
← Back
Data updated: Jun 28, 2026

UNIVERSAL INDUSTRIAL GASES, INC

Pharma
Pharmaceuticals

UNIVERSAL INDUSTRIAL GASES, INC is a pharmaceutical company with 2 FDA-approved products.

2018
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

UNIVERSAL INDUSTRIAL GASES, INC's Key Drugs

UNIVERSAL INDUSTRIAL GASES, INC's core commercial portfolio centers on NITROGEN, NF, OXYGEN, USP — its most strategically important drugs approved in the last 15 years.

NITROGEN, NF
Other
Approved 2013
OXYGEN, USP
Respiratory
Approved 2013

UNIVERSAL INDUSTRIAL GASES, INC's Recent FDA Approvals

New NDA/BLA approvals for UNIVERSAL INDUSTRIAL GASES, INC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

UNIVERSAL INDUSTRIAL GASES, INC's Therapeutic Areas

Disease areas where UNIVERSAL INDUSTRIAL GASES, INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

UNIVERSAL INDUSTRIAL GASES, INC Pipeline Snapshot

Active clinical trials for UNIVERSAL INDUSTRIAL GASES, INC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITROGEN, NF leads revenue
  • • 2 key drugs tracked

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling